AHA 2021 statement on preventing viridans group streptococcal endocarditis: who still premedicates, for which procedures, and why clindamycin came off the list

What it says#

The 2021 scientific statement is an audit of the 2007 guideline rather than a rewrite of it. The 2007 document had scaled the underlying conditions back to four categories thought to confer the highest risk of an adverse outcome from viridans group streptococcal infective endocarditis. The 2021 writing group, which included members of the American Dental Association, the Infectious Diseases Society of America and the American Academy of Pediatrics alongside the AHA, searched MEDLINE for evidence on compliance with the 2007 recommendations and on the frequency of and morbidity or mortality from VGS IE since they were published. It found good general awareness of the 2007 guidelines but variable compliance, and no convincing evidence that the frequency, morbidity or mortality of VGS IE has increased since 2007. Its conclusion is that there are no recommended changes to the 2007 prevention guidelines.

The reasoning behind the restraint is set out as key findings. VGS IE is much more likely to develop as a result of transient bacteremia from routine daily activities such as chewing food and toothbrushing than from a dental procedure. An exceedingly small number of cases could be prevented by prophylaxis before a dental procedure even if prophylaxis were 100% effective. If it does prevent a very small number of cases, it should be suggested only for patients at the highest risk of a bad outcome. And prophylaxis is not suggested solely on the basis of an increased lifetime risk of acquiring endocarditis. The counterweight the statement offers is not a drug: maintenance of good oral health and regular access to dental care are considered more important to prevent VGS IE than prophylaxis before a dental procedure, and the document suggests at-risk patients have biannual dental examinations where such care is available.

Two gates have to be open before a dose is given. The first is the patient. The conditions for which prophylaxis is suggested are a prosthetic cardiac valve or prosthetic material, which covers a prosthetic valve in place, transcatheter implantation of prosthetic valves, valve repair with devices including annuloplasty rings or clips, and left ventricular assist devices or an implantable heart; previous, relapsed or recurrent infective endocarditis; four congenital heart disease situations, namely unrepaired cyanotic CHD including palliative shunts and conduits, a completely repaired defect with prosthetic material or a device placed by surgery or transcatheter during the first six months after the procedure, repaired CHD with residual defects at or adjacent to the site of a prosthetic patch or device, and surgical or transcatheter pulmonary artery valve or conduit placement such as a Melody valve or Contegra conduit; and cardiac transplantation recipients who develop cardiac valvulopathy. Prophylaxis is not suggested for pacemakers and similar implantable electronic devices, septal defect closure devices once complete closure is achieved, peripheral vascular grafts and patches including those used for hemodialysis, coronary artery and other vascular stents, CNS ventriculoatrial shunts, vena cava filters, or pledgets.

The second gate is the procedure. Prophylaxis is suggested for all dental procedures that involve manipulation of gingival tissue or the periapical region of teeth or perforation of the oral mucosa, and not for anesthetic injections through noninfected tissue, radiographs, removable prosthodontic or orthodontic appliances, orthodontic adjustments and brackets, shedding of primary teeth, or bleeding from trauma to the lips or oral mucosa.

The regimen is a single dose 30 to 60 minutes before the procedure. By mouth: amoxicillin, 2 g for adults and 50 mg/kg for children. Unable to take oral medication: ampicillin 2 g intramuscular or intravenous, or cefazolin or ceftriaxone 1 g intramuscular or intravenous, each 50 mg/kg intramuscular or intravenous for children. Allergic to penicillin or ampicillin and able to take oral medication: cephalexin 2 g for adults and 50 mg/kg for children, or another first- or second-generation oral cephalosporin in equivalent adult or pediatric dosing; or azithromycin or clarithromycin 500 mg for adults and 15 mg/kg for children; or doxycycline 100 mg for adults and, for children, 2.2 mg/kg under 45 kg or 100 mg over 45 kg. Allergic and unable to take oral medication: cefazolin or ceftriaxone 1 g intramuscular or intravenous, 50 mg/kg for children. Cephalosporins should not be used in anyone with a history of anaphylaxis, angioedema or urticaria with penicillin or ampicillin. Clindamycin is no longer recommended for prophylaxis before a dental procedure; the ADA's page gives the reason in the AHA's words, that clindamycin may cause more frequent and severe reactions than other antibiotics used for prophylaxis, including Clostridioides difficile infection. The pediatric doses are weight-based, so the child has to be weighed at the visit rather than estimated from age.

Who it applies to#

This is a scientific statement from the AHA, not a law and not a standard of care, and the treating dentist decides for the patient in the chair. It reaches a dental practice through the ADA, whose Council on Scientific Affairs approved the 2007 AHA guidelines as they relate to dentistry in 2008 and whose oral health topic page now carries the 2021 update. It applies to every operator in the office who performs a procedure that manipulates gingiva or the periapex or perforates mucosa, which means hygiene as much as surgery.

For children, the same conditions and the same table apply, and the AAPD reprints them with permission in its own best practice, covered here in aapd-antibiotic-prophylaxis-dental-patients-at-risk-2026, which adds an immunocompromise list of its own. Prosthetic joints are a separate document: the ADA's 2015 clinical practice guideline states that in general, for patients with prosthetic joint implants, prophylactic antibiotics are not recommended prior to dental procedures to prevent prosthetic joint infection, and the ADA now frames timing and any rare use of prophylaxis as shared decision making among the dentist, the orthopedic team and the patient rather than routine delays or automatic premedication.

The ADA page also answers the three questions that come up at the front desk. If the dose is inadvertently not administered before the procedure, it may be administered up to 2 hours after. If a patient who premedicated properly one day returns the next day for another procedure warranting premedication, the regimen is repeated, because a single loading dose is given to cover the bacteremia of a single procedure. And if the patient is already taking an antibiotic for another condition, the dentist selects an antibiotic from a different class.

What changed#

Nothing changed about who is covered. The 2021 statement examined the interval evidence and made no revisions to the 2007 patient categories, the procedure triggers or the emphasis on oral health. What changed is the drug list: clindamycin, which sat in the 2007 alternative regimens, is no longer recommended, and doxycycline appears among the alternatives for a patient who cannot take a penicillin, a cephalosporin or a macrolide. Two errata have been issued against the statement, in Circulation 2021;144(9):e192 and Circulation 2022;145(17):e868. The 2017 AHA and ACC focused update on valvular heart disease reinforced the same recommendations and pressed the point about oral health, and the ADA's answer to the 2015 Lancet analysis from the United Kingdom, which correlated a more restrictive national policy with a rise in endocarditis cases, is that the study was retrospective and observational, that its authors said their data do not establish a causal association, and that dentists should continue to use the AHA and ACC guidelines.

Where the source is#

The link under the title is the statement's article page at ahajournals.org, which is the source of record for Circulation 2021;143(20):e963-e978. That site refused automated access in this session, returning 403 to every user agent tried, so the text above was assembled from three sources that did load: the PubMed record for the statement (PMID 33853363) and for its JADA adaptation (PMID 34711348, JADA 2021;152(11):886-902.e2), which carry the background, methods and conclusions verbatim; the ADA's own oral health topic page on antibiotic prophylaxis prior to dental procedures, which lists the patient selection criteria, the procedure trigger, the clindamycin change and the practical rules about missed and repeated doses; and the AAPD's 2026 best practice PDF, which reprints the AHA condition, procedure and regimen tables in full, with permission and under the AHA's copyright notice for the 2021 statement. The regimen figures above were read from that reprint. The AHA's own full text is behind the publisher's wall, and the two errata are cited but were not read here. This entry reports a guideline; it is not a prescription, and the treating dentist decides.